The efficacy of entecavir (ETV) in chronic hepatitis B (CHB) patients who were 45 exposed to lamivudine (LAM), but had no detectable LAM-resistance (LAM-R) is not 46 well evaluated. In this study, we aimed to evaluate whether the probability of 47 developing genotypic resistance to ETV in LAM-exposed patients with/without LAM-R 48 is comparable to that in antiviral-naïve patients. This retrospective cohort study 49 included 500 consecutive patients with CHB who started ETV monotherapy at a single 50 tertiary hospital in Korea. The patients were divided into three groups: NA-naïve 51 patients (group 1, n=142), patients who were ever exposed to LAM with no currently or 52 previously detected LAM-R (group 2, n=233), and patients with LAM-R when starting 53 ETV (group 3, n=125). Overall median ETV treatment duration was 48.7 months.
Introduction

68
Entecavir (ETV) is an orally administered guanosine analogue that has been approved 69 for treatment of chronic hepatitis B (CHB). In antiviral-naïve CHB patients, ETV has 70 shown excellent antiviral efficacy with remarkably low probabilities of genotype 71 resistance (1.2%) and virologic breakthrough (0.8%) for up to five years of treatment (1).
72
In contrast to antiviral-naïve patients, the rates of genotypic resistance to ETV are much 73 higher in patients with lamivudine (LAM)-resistance (LAM-R) (i.e., 51% of five-year 74 cumulative probability) (1). Consequently, ETV is now recommended as one of the first-75 line therapeutic regimens for antiviral-naïve patients with CHB, but not for patients 76 who developed LAM-R (2-4).
77
The emergence of LAM-R variants has been relatively frequent even in antiviral- 
89
Although ETV may not be recommended to those who developed LAM-R variants, the 90 applicability of ETV in those patients who were exposed to LAM, without previously or 91 currently detected LAM-R variants remains unclear. In this study, therefore, we aimed 92 to compare the risk of developing virologic breakthrough and genotypic resistance to 93 ETV (ETV-R) in patients who were previously exposed to LAM without previous or associated with genotypic resistance to LAM (i.e. rtL180M, rtL180V, rtM204I, rtM204V, 105 and rtM204S). Virologic breakthrough was defined as at least a 1 log 10 increase in 106 serum HBV DNA (IU/mL), compared to the on-treatment nadir (12). Genotypic ETV-R 107 referred to the detection of HBV variants with amino acid substitutions that conferred 108 attenuated susceptibility to ETV (i.e. rtT184G, rtT184S, rtT184A, rtT184I, rtT184L, 109 rtS202G, rtS202I and rtM250V) by direct sequencing method (13, 14) . from serum samples and the HBV polymerase gene was amplified using nested PCR.
130
The Big-Dye terminator version 3.1 ready reaction cycle sequencing kit (Applied
131
Biosystems, Foster City, CA) with an ABI Prism 3730 genetic analyzer (Perkin-Elmer,
132
Foster City, CA) was used to perform the cycle sequencing reaction. Genotypic The primary endpoints of this study were the emergence of genotypic ETV-R LAM-R at baseline). Table 1 shows the baseline characteristics of these three groups.
172
One hundred fifteen patients (49.4%) in group 2 had discontinued LAM without LAM-R 
178
The median overall LAM treatment duration of group 3 (38.3 months; range, 6.0-179 121.1 months) was longer than that of group 2 (23.5 months; range, 2.0 -93.5 months)
180
(P<0.001). Sixty-two patients (49.6%) had experienced virologic breakthrough during 181 prior LAM treatment in group 3, which was significantly more frequent than that in the 182 group 2 (76 patients; 32.6%) (P < 0.001).
183
Nineteen patients (8.2%) in group 2 and 9 patients (7.2%) in group 3 showed 184 primary non-response at 3 months of LAM treatment, and there was no significant group 1 showed significantly more profound HBV DNA suppression (-6.31 ± 1.59 log 10 210 IU/mL) than group 2 (-5.09 ± 2.80 log 10 IU/mL, P < 0.001) as well as group 3 (-3.91 ± 211 2.66 log 10 IU/mL, P < 0.001) (Fig.1A) . 95% CI, 0.004-0.087; P < 0.001) (Fig.3) after 2 years of ETV therapy in group 2 of our study. Therefore, the conclusion of the had significantly lower probability of developing ETV-R (P < 0.001 by log rank test).
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